Abstract CT205: Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial
Matthew P. Goetz(Mayo Clinic), Steven C. Quay(Aptevo Therapeutics (United states)), Pooja Advani(Jacksonville College), Sarah A. Buhrow(Mayo Clinic), Amy C. Degnim(Mayo Clinic in Arizona), Felipe Batalini(Beth Israel Deaconess Medical Center), Patricia A. Cronin(Mayo Clinic in Arizona), Joel M. Reid(Children's Hospital of Philadelphia), Judy C. Boughey(Mayo Clinic in Arizona), John R. Hawse(Mayo Clinic in Arizona), Swaathi Jayaraman(Johns Hopkins University), Katie N. Hunt(Mayo Clinic), James W. Jakub(Mayo Clinic in Arizona), Roberto A. Leon‐Ferre(Mayo Clinic), Lida A. Mina(Mayo Clinic in Arizona), Mara A. Piltin(Mayo Clinic), Vera J. Suman(Mayo Clinic in Arizona), James N. Ingle(Mayo Clinic), Karthik V. Giridhar(WinnMed), Heather Fraser(Aptevo Therapeutics (United states)), Matthew J. Schellenberg(Mayo Clinic)
Cited by 1
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
|Clinical Cancer Research|2013|744